Combination therapy for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether taking tislelizumab plus nintedanib after initial radiation and chemotherapy can help keep limited-stage small cell lung cancer from coming back. It is for people who have finished induction treatment and are in good overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have limited-stage small cell lung cancer (cancer that has not spread too far).
- You have finished initial radiation and chemotherapy but have not had any other cancer treatment for this lung cancer.
- You are at least 18 years old and in generally good health (able to do most daily activities).
- Your blood counts, kidney, and liver function are within acceptable ranges.
- You are willing to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that combines a short course of radiation with chemotherapy and an immunotherapy drug (adebrelimab). It is for people with limited-stage small cell lung cancer who haven't had treatment yet.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) together with chest radiation to treat small cell lung cancer that hasn't spread widely and cannot be removed with surgery. The goal is to see if this combination helps people live longer and controls their cancer better.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
Hear when a new Limited-stage Small Cell Lung Cancer (LS-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.